Sweden
· Delayed Price · Currency is SEK SUS Statistics
Total Valuation
Surgical Science Sweden AB has a market cap or net worth of SEK 6.33 billion. The enterprise value is 5.66 billion.
| Market Cap | 6.33B |
| Enterprise Value | 5.66B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Surgical Science Sweden AB has 51.03 million shares outstanding. The number of shares has increased by 0.35% in one year.
| Shares Outstanding | 51.03M |
| Shares Change (YoY) | +0.35% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.64% |
| Owned by Institutions (%) | 52.93% |
| Float | 37.43M |
Valuation Ratios
The trailing PE ratio is 32.00 and the forward PE ratio is 28.62.
| PE Ratio | 32.00 |
| Forward PE | 28.62 |
| PS Ratio | 7.55 |
| PB Ratio | 1.38 |
| P/FCF Ratio | 44.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.14, with an EV/FCF ratio of 40.02.
| EV / Earnings | 28.63 |
| EV / Sales | 6.75 |
| EV / EBITDA | 29.14 |
| EV / EBIT | 36.78 |
| EV / FCF | 40.02 |
Financial Position
The company has a current ratio of 4.15
| Current Ratio | 4.15 |
| Quick Ratio | 3.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 4.36% and return on invested capital (ROIC) is 2.12%.
| Return on Equity (ROE) | 4.36% |
| Return on Assets (ROA) | 1.95% |
| Return on Capital (ROIC) | 2.12% |
| Revenue Per Employee | 3.16M |
| Profits Per Employee | 746,128 |
| Employee Count | 265 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.60% in the last 52 weeks. The beta is 1.00, so Surgical Science Sweden AB's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -23.60% |
| 50-Day Moving Average | 128.55 |
| 200-Day Moving Average | 151.64 |
| Relative Strength Index (RSI) | 42.74 |
| Average Volume (20 Days) | 91,731 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Surgical Science Sweden AB had revenue of SEK 838.25 million and earned 197.72 million in profits. Earnings per share was 3.87.
| Revenue | 838.25M |
| Gross Profit | 574.26M |
| Operating Income | 153.90M |
| Pretax Income | 236.52M |
| Net Income | 197.72M |
| EBITDA | 179.07M |
| EBIT | 153.90M |
| Earnings Per Share (EPS) | 3.87 |
Balance Sheet
| Cash & Cash Equivalents | 667.08M |
| Total Debt | n/a |
| Net Cash | 667.08M |
| Net Cash Per Share | 13.07 |
| Equity (Book Value) | 4.59B |
| Book Value Per Share | 90.02 |
| Working Capital | 807.10M |
Cash Flow
In the last 12 months, operating cash flow was 151.18 million and capital expenditures -9.76 million, giving a free cash flow of 141.43 million.
| Operating Cash Flow | 151.18M |
| Capital Expenditures | -9.76M |
| Free Cash Flow | 141.43M |
| FCF Per Share | 2.77 |
Margins
Gross margin is 68.51%, with operating and profit margins of 18.36% and 23.59%.
| Gross Margin | 68.51% |
| Operating Margin | 18.36% |
| Pretax Margin | 28.22% |
| Profit Margin | 23.59% |
| EBITDA Margin | 21.36% |
| EBIT Margin | 18.36% |
| FCF Margin | 16.87% |
Dividends & Yields
Surgical Science Sweden AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.35% |
| Shareholder Yield | -0.35% |
| Earnings Yield | 3.12% |
| FCF Yield | 2.24% |
Stock Splits
The last stock split was on May 25, 2020. It was a forward split with a ratio of 5.
| Last Split Date | May 25, 2020 |
| Split Type | Forward |
| Split Ratio | 5 |